The cost-utility of photodynamic therapy in eyes with neovascular macular degeneration - A value-based reappraisal with 5-year data

American Journal of Ophthalmology

Volumn 140, Issue 4, 2005, Pages 679.e1-679.e10

  Brown, Gary C ^a,b,d,e   Brown, Melissa M ^a,c,d,e   Campanella, Joseph ^a   Beauchamp, George R ^a,f  

^a CENTER FOR VALUE BASED MEDICINE   (United States)

^b WILLS EYE HOSPITAL   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d Eye Research Institute   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOPORPHYRIN DERIVATIVE; PHOTOSENSITIZING AGENT;

AGED; ALLERGIC REACTION; ARTICLE; BACKACHE; CONTROLLED STUDY; COST OF ILLNESS; COST UTILITY ANALYSIS; DRUG COST; HEALTH CARE COST; HEALTH CARE QUALITY; HUMAN; INJECTION SITE REACTION; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MEDICARE; MICROANGIOPATHY; PHOTODYNAMIC THERAPY; PHOTOSENSITIVITY DISORDER; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; SENSITIVITY ANALYSIS; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL DISORDER;

EID: 26844485888     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2005.04.061     Document Type: Article

References (46)

1. R. Klein, B.E.K. Klein, S.C. Tomany, S.M. Meuer, E.H. Huang Ten-year incidence and progression of age-related maculopathy The Beaver Dam Eye Study Ophthalmology 109 2002 1767 1779
2. D.S. Friedman, B.J. O'Colmain, B. Munoz Eye Diseases Prevalence Research Group Prevalence of age-related macular degeneration in the United States Arch Ophthalmol 122 2004 564 572
3. Macular Photocoagulation study Group Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration. Updated findings from two clinical trials Arch Ophthalmol 107 1993 1374 1380
4. Brown GC, Brown MM, Sharma S, Roth Z, Campanella J, Beauchamp G. The burden of age-related macular degeneration. A value-based analysis. Curr Opin Ophthalmol. Forthcoming.
5. G.C. Brown, M.M. Brown, S. Sharma Difference between ophthalmologist and patient perceptions of quality-of-life associated with age-related macular degeneration Can J Ophthalmol 35 2000 27 32
6. J.D. Stein, M.M. Brown, G.C. Brown, S. Sharma, H. Hollands Quality of life with macular degeneration. Perceptions of patients, clinicians and community members Brit J Ophthalmol 87 2003 8 12
7. Treatment of Age-related Macular Degeneration With Photodynamic Therapy (TAP) Study Group Photodynamic therapy for subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. One-year results of 2 randomized clinical trials - TAP Report 1 Arch Ophthalmol 117 1999 1329 1345
8. Treatment of Age-related Macular Degeneration With Photodynamic Therapy (TAP) Study Group Photodynamic therapy for subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. Two-year results of 2 randomized clinical trials - TAP Report 2 Arch Ophthalmol 119 2001 198 207
9. Treatment of Age-related Macular Degeneration With Photodynamic Therapy (TAP) Study Group Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration. Three-year results of an open-label extension of 2 randomized clinical trials - TAP Report No. 5 Arch Ophthalmol 120 2002 1307 1314
10. S. Sharma, G.C. Brown, M.M. Brown, H. Hollands, G.K. Shah The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration Ophthalmology 108 2001 2051 2059
11. M.M. Brown, G.C. Brown, S. Sharma Value-based medicine to evidence-based medicine 2005 AMA Press Chicago
12. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration. Additional information regarding baseline lesion composition's impact on vision outcomes - TAP Report No. 3 Arch Ophthalmol 120 2002 1443 1454
13. D. Husain, J.W. Miller, N. Michaud, E. Connolly, T.J. Flotte, E.S. Gragoudas Intravenous infusion of liposomal benzoporphrin derivative for photodynamic therapy of experimental choroidal neovascularization Arch Ophthalmol 114 1996 978 985
14. E. Arias United States Life Tables, 2002 National Vital Statistics Reports 53 2004 1 39
15. I.L. Bailey, J.E. Lovie New design principles for visual acuity letter charts Am J Optom Physiol Opt 53 1976 740 745
16. M.M. Brown, G.C. Brown, S. Sharma, J. Landy Health care economic analyses and value-based medicine Surv Ophthalmol 48 2003 204 223
17. M.M. Brown, G.C. Brown, S. Sharma, J. Landy Quality of life with visual acuity loss from diabetic retinopathy and age-related macular degeneration Arch Ophthalmol 120 2002 481 484
18. M.M. Brown, G.C. Brown, S. Sharma, J. Kistler, H. Brown Utility values associated with blindness in an adult population Br J Ophthalmol 85 2001 327 331
19. G.C. Brown Vision and quality of life Trans Am Ophthalmol Soc 97 1999 473 512
20. M.M. Brown, G.C. Brown, S. Sharma, G. Shah Utility values and diabetic retinopathy Am J Ophthalmol 128 1999 324 330
21. G.C. Brown, M.M. Brown, S. Sharma, J. Kistler Utility values associated with age-related macular degeneration Arch Ophthalmol 118 2000 47 51
22. G.C. Brown, M.M. Brown, S. Sharma, H. Brown Patient perceptions of bilateral visual loss. A utility value analysis Int Ophthalmol 22 2000 307 312
23. M.M. Brown, G.C. Brown, S. Sharma, H. Brown, B. Busbee Quality-of-life associated with unilateral and bilateral good vision Ophthalmology 108 2001 643 647
24. S. Sharma, G.C. Brown, M.M. Brown, H. Hollands, R. Robbins, G. Shah Validity of the time trade-off and standard gamble methods of utility assessment in retinal patients Br J Ophthalmol 86 2002 493 496
25. S. Sharma, A. Oliver, J. Bakal, H. Hollands, G.C. Brown, M.M. Brown Utilities associated with diabetic retinopathy results from a Canadian sample Br J Ophthalmol 87 2003 259 261
26. M.R. Gold, D.L. Patrick, G.W. Torrance Identifying and valuing outcomes M.R. Gold J.E. Siegel L.B. Russell M.C. Weinstein Cost-effectiveness in health and medicine 1996 Oxford University Press New York 82 134
27. Medicare Fee Schedule. From the Internet @ cms.hhs.gov, accessed July 21, 2004.
28. Medicare Coverage Database. From the Internet @ http://www.cms.hhs.gov/ mcd/viewlmrp.asp?lmrp_id=13561&lmrp_version=2&show=all, accessed July 21, 2004.
29. Centers for Medicare and Medicaid Services April 2004 Quarterly Drug Fee Updates. From the Internet @ http://www.empiremedicare.com/fees/nj/NJ04drugupda. pdf, accessed July 27, 2004.
30. Current Procedural Terminology, CPT™ 2004 2004 American Medical Association Chicago
31. M.F. Drummond, B. O'Brien, G.L. Stoddart, G.W. Torrance Methods for the economic evaluation of health care programs 2000 Oxford University Press Oxford 139 199
32. A. Damodaran Corporate finance, theory and practice 1997 John Wiley & Sons, Inc New York 37 65
33. M.C. Weinstein, J.E. Siegel, M.R. Gold, M.S. Kamlet, L.B. Russell Recommendations of the panel on cost-effectiveness in health and medicine JAMA 276 1996 1253 1258
34. J.E. Siegel, M.C. Weinstein, L.B. Russell, M.R. Gold Recommendations for reporting cost-effectiveness analyses. Panel on cost-effectiveness in health and medicine JAMA 276 1996 1339 1341
35. A. Laupacis, D. Feeny, A.S. Detsky, P.X. Tugwell How attractive does a new technology have to be to warrant adoption and utilization. Tentative guidelines for using clinical and economic evaluations Can Med Assoc J 146 1992 473 481
36. G.R. Heudebert, R.M. Centor, J.C. Klapow What is heartburn worth? A cost-utility analysis of management strategies J Gen Intern Med 15 2000 175 182
37. D.F. Kallmes, M.H. Kallmes Cost-effectiveness of angiography performed during surgery for ruptured intracranial aneurysms AJNR Am J Neurorad 18 1997 1453 1462
38. C. Hopley, G. Salkeld, P. Mitchell Cost utility of photodynamic therapy for predominantly classic neovascular age related macular degeneration Br J Ophthalmol 88 2004 982 987
39. D.H. Smith, P. Fenn, M. Drummond Cost-effectiveness of photodynamic therapy with verteporfin for age-related macular degeneration the UK case Br J Ophthalmol 88 2004 1107 1112
40. S. Sharma, G.C. Brown, M.M. Brown Converting visual acuity to utilities Can J Ophthalmol 35 2000 267 272
41. Food & Drug Administration. Recalls, market withdrawals and safety alerts. From the Internet @ fda.gov, accessed April 24, 2005.
42. A. Laupacis, P. Keown, N. Pus A study of the quality of life and cost-utility of renal transplantation Kidney Int 50 1996 235 242
43. G.C. Brown, M.M. Brown, S. Sharma Incremental cost-effectiveness of laser therapy for subfoveal choroidal neovascularization Ophthalmology 107 2000 1374 1380
44. Ellwein EB. Statistics and Data. Updating the Hu 1981 Estimates of the economic costs of visual disorders and disabilities. From the Internet @ http://www.nei.nih.gov/eyedata/hu_estimates.asp, accessed December 1, 2004.
45. T. Realini, R.D. Fechtner 56,000 ways to treat glaucoma Ophthalmol 109 2002 1955 1956
46. E.S. Gragoudas, A.P. Adamis, E.T. Cunningham, M. Feinsod, D.R. Guyer VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group New Eng J Med 351 2004 2805 2816